A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers
These findings suggest that the specific microenvironment may be affected by the absence of non-epithelial cell types, although hormone-regulatory mechanisms are present in the organoids
IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1
The difference in the glucose lowering effect observed in the trial may not necessarily reflect the effect that will be observed in the care setting where insulin glargine dosage can be different than that used in the trial
Severe side effects include: Gallbladder problems Low blood sugar Rapid heartbeat Kidney problems Increased low blood sugar Mounjaro Mounjaro is the more common name for tirzepatide, another injectable medication used to treat type 2 diabetes
Hll, K., Morstein, J
